Shanghai Total Other Income Expense Net from 2010 to 2024
| 601607 Stock | 21.37 0.07 0.33% |
Total Other Income Expense Net | First Reported 2010-12-31 | Previous Quarter -1.5 B | Current Value -1.4 B | Quarterly Volatility 1.1 B |
Check Shanghai Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shanghai Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 1.7 B, Selling General Administrative of 16.4 B or Total Revenue of 273.3 B, as well as many indicators such as . Shanghai financial statements analysis is a perfect complement when working with Shanghai Pharmaceuticals Valuation or Volatility modules.
Shanghai | Total Other Income Expense Net |
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.